Quebec Cancer Center is First in Canada to Treat Cancer Patients Using the Accuray Radixact® System

Rhea-AI Summary

Accuray Incorporated (NASDAQ: ARAY) partners with Montérégie Integrated Cancer Center to introduce Radixact System for cancer treatment in Quebec. The system includes ClearRT™ and Synchrony® technologies to enhance treatment outcomes and minimize side effects. The center aims to set a new standard in precision and accuracy for radiation therapy.

Oncology Doctor

The introduction of the Radixact System by Accuray at the Montérégie Integrated Cancer Center represents a significant advancement in cancer treatment technology. The system's ability to produce diagnostic-like quality CT images and adapt to tumor movement in real-time through its ClearRT and Synchrony technologies respectively, can lead to more precise radiation doses being administered. This precision is crucial, as it potentially reduces the damage to surrounding healthy tissues and decreases the side effects for patients. Such technological enhancements could improve overall patient quality of life and may also reduce the need for additional treatments, which can be both physically and financially taxing for patients.

Furthermore, the system's versatility in treating a wide range of tumors, including complex cases and those located in challenging positions, broadens the scope of patients who can benefit from radiation therapy. This could result in an increased demand for Accuray's technologies, positioning the company as a key player in the radiation therapy market. The long-term impact on patient outcomes and healthcare costs will be an important area to monitor as the technology becomes more widely adopted.

Medical Research Analyst

The deployment of the Radixact System at a leading Canadian cancer center is indicative of Accuray's commitment to innovation and could signal a competitive edge in the radiation therapy market. By being the first in Canada to utilize this advanced system, the Montérégie Integrated Cancer Center may set a precedent for other institutions, potentially leading to a wider adoption of Accuray's technology. This could have a positive impact on the company's market share and financial performance, particularly if the system demonstrates a significant improvement in patient outcomes compared to existing radiation therapy methods.

Investors and stakeholders should consider the potential for increased revenue streams from both the sale of new systems and the ongoing service and maintenance contracts that typically accompany such high-tech medical devices. The announcement of a second system installation scheduled for mid-2024 suggests a growing interest and commitment to Accuray's technology, which could be a positive indicator for the company's future growth prospects.

Healthcare Industry Analyst

The healthcare industry is continually seeking ways to improve efficiency and patient care and the Radixact System's impact on radiation therapy department workflows is noteworthy. With the ability to rapidly deliver treatments and improve patient throughput, healthcare providers could see a reduction in wait times and increased capacity for treating patients. This operational efficiency may translate into better resource allocation and potentially lower operational costs for healthcare facilities.

From an industry perspective, the integration of advanced technologies like ClearRT and Synchrony in radiation therapy is a step forward in personalized medicine. As healthcare continues to move towards more tailored treatments, companies like Accuray that invest in such innovations may gain a strategic advantage. The emphasis on improved patient outcomes aligns with broader industry trends prioritizing value-based care, which could enhance Accuray's reputation and strengthen its position in the market.

• Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is a center of excellence and recognized leader in the treatment of cancer in the province of Quebec
• The Radixact System is equipped with ClearRT™ and Synchrony^®, advanced technologies designed to improve treatment outcomes for more patients each day

MADISON, Wis., Feb. 13, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the team at Quebec's Montérégie Integrated Cancer Center, part of Charles-LeMoyne Hospital, is the first in Canada to treat cancer patients using the company's Radixact^® radiation therapy delivery system. According to the Quebec Cancer Foundation, "on average in Quebec, someone learns that they have cancer every 8 minutes¹," reinforcing the need for innovative new care options like the Radixact System that effectively manage the disease while minimizing the radiation dose to healthy tissue and associated risk of side effects that can impact daily life. A second Radixact System is scheduled to be installed mid-2024.

The Radixact System at the Montérégie center has been augmented with the Accuray exclusive ClearRT™ helical fan-beam kVCT imaging solution and Synchrony^® motion adaptation technology. ClearRT can produce exceptional, diagnostic-like quality CT images while Synchrony enables clinicians to track, detect and correct for tumor movement in real-time, providing medical care teams with the tools to help improve radiation therapy department workflows and patient outcomes, and rapidly deliver treatments.

"Our goal at Accuray is to design radiation therapy solutions that can take on the most complex challenges — while making commonly treatable cases even easier — so patients get back to living their lives, faster. We are honored to partner with the Montérégie Integrated Cancer Center team to bring a new approach for the treatment of cancer to the people in the province of Quebec. With the installation of the Radixact System, ClearRT and Synchrony, the Montérégie team is setting a new standard for precision and accuracy in radiation therapy and making this form of care an option for more cancer patients," said Suzanne Winter, president and CEO of Accuray.

The Radixact System provides a non-invasive option for the treatment of a wide range of cancerous and non-cancerous tumors throughout the body — from small to large tumors, multiple tumors, those located in hard-to-reach areas and recurrent tumors, to cancers of the skin and blood. The system can be used in combination with surgery, chemotherapy and other medications. It also can be used as part of the pre-conditioning regimen before a bone marrow transplant, either alone or with chemotherapy, to neutralize any cancer in the marrow.

Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, expectations regarding the treatment of cancer in Quebec, Canada; expectations regarding installation of a second Radixact at the Monteregi Integrated Cancer Center; clinical applications; clinical results; patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products, including new product innovations and releases; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace; and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 7, 2024, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com

¹ https://cancerquebec.ca/en/information-about-cancer/the-cancer/statistics/#:~:text=In%202023%2C%2067%2C548%20Quebecers%20were,of%20aging%20and%20population%20growth.

View original content to download multimedia:https://www.prnewswire.com/news-releases/quebec-cancer-center-is-first-in-canada-to-treat-cancer-patients-using-the-accuray-radixact-system-302060306.html

SOURCE Accuray Incorporated

What technologies are integrated into the Radixact System for cancer treatment?

The Radixact System includes ClearRT™ helical fan-beam kVCT imaging solution and Synchrony® motion adaptation technology.

What is the significance of the partnership between Accuray and Montérégie Integrated Cancer Center?

The partnership aims to bring a new approach for cancer treatment to the people in Quebec by setting a new standard for precision and accuracy in radiation therapy.

How does the Radixact System benefit cancer patients?

The system provides a non-invasive treatment option for a wide range of cancerous and non-cancerous tumors, enhancing treatment outcomes and minimizing side effects.

What is the goal of Accuray in designing radiation therapy solutions?

Accuray aims to design solutions that can address complex challenges and make treatable cases easier for patients to resume their daily lives faster.

What additional technology is scheduled to be installed at Montérégie Integrated Cancer Center in mid-2024?

A second Radixact System is scheduled to be installed at the Montérégie center, enhancing their capabilities for cancer treatment.